Compare ONL & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | NERV |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 166.4M |
| IPO Year | 2021 | 2014 |
| Metric | ONL | NERV |
|---|---|---|
| Price | $2.19 | $2.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | ★ 333.0K | 105.4K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $147,647,000.00 | $41,175,600.00 |
| Revenue This Year | $1.67 | N/A |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $2.24 |
| 52 Week High | $3.05 | $8.80 |
| Indicator | ONL | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 27.35 |
| Support Level | $1.91 | N/A |
| Resistance Level | $2.59 | $5.69 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.75 | 4.83 |
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.